Aldurazyme market report flags growth in rare-disease treatment demand
The Business Research Company says the Aldurazyme market is expanding on the back of more clinical trials, higher healthcare spending and broader rare-disease screening. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2035.
Why it matters: - Aldurazyme treats mucopolysaccharidosis type I, a rare inherited disorder with severe health risks when glycosaminoglycans build up untreated. - The market matters because broader screening, better reimbursement and more specialized care could expand access to enzyme replacement therapy for MPS I patients. - The report frames Aldurazyme as part of the wider orphan-drug market, where policy support and research spending can quickly change adoption rates.
What happened: - The Business Research Company published its “Aldurazyme Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035” on Oct. 29, 2026. - The report says the Aldurazyme market has been shaped by limited treatment options for MPS I, better rare-disease diagnostics, recombinant enzyme innovation and orphan-drug regulatory frameworks. - The report also says future growth will be driven by newborn screening expansion, rare-disease investment, higher patient survival, more specialized care facilities and stronger reimbursement support. - The company offered a free sample of the report and a full report.
The details: - Aldurazyme is a prescription enzyme replacement therapy that provides a synthetic form of α-L-iduronidase. - The therapy is designed to help break down glycosaminoglycans, which accumulate in tissues when the enzyme is missing. - The report says Aldurazyme can reduce GAG accumulation and improve symptoms, which can support quality of life for people with MPS I. - A key growth driver is the rising number of clinical trials focused on rare-disease treatment. - ClinicalTrials.gov reported in February 2024 that clinical trial publications rose to 5,063 in 2023 from 4,024 in 2022. - The report also points to rising healthcare expenditure as a market tailwind. - The UK’s Office for National Statistics reported in May 2024 that nominal healthcare spending rose 5.6% from 2022 to 2023, after 0.9% growth the year before. - UK government healthcare spending reached $302 billion in 2023 and represented 81.9% of total healthcare financing. - In 2025, North America was the largest regional market for Aldurazyme. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.
Between the lines: - The market outlook is less about a single drug and more about whether health systems can identify rare-disease patients earlier and pay for long-term treatment. - More trial activity suggests continued scientific attention to MPS I and related therapies, which can strengthen physician confidence and market visibility. - The regional split hints at a mature market in North America and a later-stage growth opportunity in Asia-Pacific as access improves.
What's next: - The report expects enzyme replacement therapy adoption to broaden during the forecast period. - The company says early diagnosis and treatment initiatives will likely expand, along with treatment centers dedicated to MPS I. - The report also expects stronger long-term management of MPS I as healthcare infrastructure and reimbursement support improve. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and trend analysis.
The bottom line: - Aldurazyme’s market appears set to grow on earlier diagnosis, more research and stronger support for rare-disease care, with North America leading now and Asia-Pacific gaining speed.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Healthcare Gazette
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.